NEW YORK: Researchers are likely to have uncovered a novel mechanism behind the ability of the common diabetes drug - metformin -- to inhibit the progression of pancreatic cancer.
Diabetic patients taking metformin have a reduced risk of developing pancreatic cancer; and among patients who develop the tumor those taking the drug may have a reduced risk of death, the study revealed.
Metformin -- a commonly used generic medication for type 2 diabetes -- decreases the inflammation and fibrosis characteristic of the most common form of pancreatic cancer, the researchers said.
This beneficial effect may be most prevalent in overweight and obese patients, the findings indicated.
"We found that metformin alleviates desmoplasia - an accumulation of dense connective tissue and tumor-associated immune cells that is a hallmark of pancreatic cancer," said lead author Dai Fukumura, associate professor of radiation oncology at Harvard Medical School in Massachusetts, US.
The study focused on pancreatic ductal adenocarcinoma -- the most common form of pancreatic cancer - which also accounts for almost 40,000 cancer death in the US ever year.
Half of those diagnosed with this form of pancreatic cancer are overweight or obese, and up to 80 percent have type-II diabetes or are insulin resistant, said the researchers.
The researchers first found that levels of hyaluronan, a component of the extracellular matrix, were 30 percent lower in tumor samples from overweight or obese patients who were taking metformin to treat diabetes than in those who did not take the drug.
In obese mouse models, the researchers found that metformin treatment reduced levels of tumor-associated macrophages by 60 percent and reduced expression of genes involved in remodeling the extracellular matrix of tumor tissue.
"Understanding the mechanism behind metformin's effects on pancreatic and other cancers may help us identify biomarkers - such as patient body weight and increased tumor fibrosis - that can identify the patients for whom metformin treatment would be most beneficial," the authors noted in a study published in the journal PLOS One.
Diabetic patients taking metformin have a reduced risk of developing pancreatic cancer; and among patients who develop the tumor those taking the drug may have a reduced risk of death, the study revealed.
Metformin -- a commonly used generic medication for type 2 diabetes -- decreases the inflammation and fibrosis characteristic of the most common form of pancreatic cancer, the researchers said.
"We found that metformin alleviates desmoplasia - an accumulation of dense connective tissue and tumor-associated immune cells that is a hallmark of pancreatic cancer," said lead author Dai Fukumura, associate professor of radiation oncology at Harvard Medical School in Massachusetts, US.
Advertisement
Half of those diagnosed with this form of pancreatic cancer are overweight or obese, and up to 80 percent have type-II diabetes or are insulin resistant, said the researchers.
Advertisement
In obese mouse models, the researchers found that metformin treatment reduced levels of tumor-associated macrophages by 60 percent and reduced expression of genes involved in remodeling the extracellular matrix of tumor tissue.
Advertisement
COMMENTS
Advertisement
Nutritionist Warns Of Metformin's Impact On Overall Health, Recommends Tips What Is Ozempic And Why Is It Gaining Attention? Explained A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared Plane With 19 On Board Crashes At Kathmandu Airport, Pilot Lone Survivor Om Birla vs Abhishek Banerjee In Lok Sabha As Trinamool Shreds Budget 2024 World's Most Powerful Passports List Released: Indian Passport Ranks At... "You Will Be Isolated If...": Amid Budget Row, MK Stalin's Message To PM These Are The Budget's Two Key Messages For The Future "Impressive": Elon Musk Praises Mark Zuckerberg In Rare Exchange Track Latest News Live on NDTV.com and get news updates from India and around the world.